Radius Planning Pivotal Trial of Cannabidiol RAD011
Radius Health has acquired the development and commercialization rights to a synthetic oral cannabidiol therapy known as RAD011, with plans to start a pivotal Phase 2/3 clinical trial in Prader-Willi syndrome (PWS) this year. Having finalized its acquisition deal with…